OBJECTIVE: Rare copy number variants (CNVs)--deletions and duplications--have recently been established as important risk factors for both generalized and focal epilepsies. A systematic assessment of the role of CNVs in epileptic encephalopathies, the most devastating and often etiologically obscure group of epilepsies, has not been performed. METHODS: We evaluated 315 patients with epileptic encephalopathies characterized by epilepsy and progressive cognitive impairment for rare CNVs using a high-density, exon-focused, whole-genome oligonucleotide array. RESULTS: We found that 25 of 315 (7.9%) of our patients carried rare CNVs that may contribute to their phenotype, with at least one-half being clearly or likely pathogenic. We identified 2 patients with overlapping deletions at 7q21 and 2 patients with identical duplications of 16p11.2. In our cohort, large deletions were enriched in affected individuals compared to controls, and 4 patients harbored 2 rare CNVs. We screened 2 novel candidate genes found within the rare CNVs in our cohort but found no mutations in our patients with epileptic encephalopathies. We highlight several additional novel candidate genes located in CNV regions. INTERPRETATION: Our data highlight the significance of rare CNVs in the epileptic encephalopathies, and we suggest that CNV analysis should be considered in the genetic evaluation of these patients. Our findings also highlight novel candidate genes for further study.
OBJECTIVE: Rare copy number variants (CNVs)--deletions and duplications--have recently been established as important risk factors for both generalized and focal epilepsies. A systematic assessment of the role of CNVs in epilepticencephalopathies, the most devastating and often etiologically obscure group of epilepsies, has not been performed. METHODS: We evaluated 315 patients with epilepticencephalopathies characterized by epilepsy and progressive cognitive impairment for rare CNVs using a high-density, exon-focused, whole-genome oligonucleotide array. RESULTS: We found that 25 of 315 (7.9%) of our patients carried rare CNVs that may contribute to their phenotype, with at least one-half being clearly or likely pathogenic. We identified 2 patients with overlapping deletions at 7q21 and 2 patients with identical duplications of 16p11.2. In our cohort, large deletions were enriched in affected individuals compared to controls, and 4 patients harbored 2 rare CNVs. We screened 2 novel candidate genes found within the rare CNVs in our cohort but found no mutations in our patients with epilepticencephalopathies. We highlight several additional novel candidate genes located in CNV regions. INTERPRETATION: Our data highlight the significance of rare CNVs in the epilepticencephalopathies, and we suggest that CNV analysis should be considered in the genetic evaluation of these patients. Our findings also highlight novel candidate genes for further study.
Authors: Jeffrey A Bailey; Zhiping Gu; Royden A Clark; Knut Reinert; Rhea V Samonte; Stuart Schwartz; Mark D Adams; Eugene W Myers; Peter W Li; Evan E Eichler Journal: Science Date: 2002-08-09 Impact factor: 47.728
Authors: S Baulac; G Huberfeld; I Gourfinkel-An; G Mitropoulou; A Beranger; J F Prud'homme; M Baulac; A Brice; R Bruzzone; E LeGuern Journal: Nat Genet Date: 2001-05 Impact factor: 38.330
Authors: R H Wallace; C Marini; S Petrou; L A Harkin; D N Bowser; R G Panchal; D A Williams; G R Sutherland; J C Mulley; I E Scheffer; S F Berkovic Journal: Nat Genet Date: 2001-05 Impact factor: 38.330
Authors: Jeong Ho Lee; My Huynh; Jennifer L Silhavy; Sangwoo Kim; Tracy Dixon-Salazar; Andrew Heiberg; Eric Scott; Vineet Bafna; Kiley J Hill; Adrienne Collazo; Vincent Funari; Carsten Russ; Stacey B Gabriel; Gary W Mathern; Joseph G Gleeson Journal: Nat Genet Date: 2012-06-24 Impact factor: 38.330
Authors: Saul A Mullen; Gemma L Carvill; Susannah Bellows; Marta A Bayly; Holger Trucks; Dennis Lal; Thoman Sander; Samuel F Berkovic; Leanne M Dibbens; Ingrid E Scheffer; Heather C Mefford Journal: Neurology Date: 2013-09-25 Impact factor: 9.910
Authors: Gabrielle Rudolf; Gaetan Lesca; Mana M Mehrjouy; Audrey Labalme; Manal Salmi; Iben Bache; Nadine Bruneau; Manuela Pendziwiat; Joel Fluss; Julitta de Bellescize; Julia Scholly; Rikke S Møller; Dana Craiu; Niels Tommerup; Maria Paola Valenti-Hirsch; Caroline Schluth-Bolard; Frédérique Sloan-Béna; Katherine L Helbig; Sarah Weckhuysen; Patrick Edery; Safia Coulbaut; Mohamed Abbas; Ingrid E Scheffer; Sha Tang; Candace T Myers; Hannah Stamberger; Gemma L Carvill; Deepali N Shinde; Heather C Mefford; Elena Neagu; Robert Huether; Hsiao-Mei Lu; Alice Dica; Julie S Cohen; Catrinel Iliescu; Cristina Pomeran; James Rubenstein; Ingo Helbig; Damien Sanlaville; Edouard Hirsch; Pierre Szepetowski Journal: Eur J Hum Genet Date: 2016-06-29 Impact factor: 4.246
Authors: Heather Olson; Yiping Shen; Jennifer Avallone; Beth R Sheidley; Rebecca Pinsky; Ann M Bergin; Gerard T Berry; Frank H Duffy; Yaman Eksioglu; David J Harris; Fuki M Hisama; Eugenia Ho; Mira Irons; Christina M Jacobsen; Philip James; Sanjeev Kothare; Omar Khwaja; Jonathan Lipton; Tobias Loddenkemper; Jennifer Markowitz; Kiran Maski; J Thomas Megerian; Edward Neilan; Peter C Raffalli; Michael Robbins; Amy Roberts; Eugene Roe; Caitlin Rollins; Mustafa Sahin; Dean Sarco; Alison Schonwald; Sharon E Smith; Janet Soul; Joan M Stoler; Masanori Takeoka; Wen-Han Tan; Alcy R Torres; Peter Tsai; David K Urion; Laura Weissman; Robert Wolff; Bai-Lin Wu; David T Miller; Annapurna Poduri Journal: Ann Neurol Date: 2014-06-13 Impact factor: 10.422